Voyager Therapeutics

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A. Kay, Krystof Bankiewicz, and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Voyager Therapeutics excels in 2022, poised for CNS therapeutic breakthroughs

Voyager Therapeutics demonstrated strong performance in 2022, leveraging key partnerships and advancements in their pipeline programs to drive innovation and growth in the CNS therapeutics space.
While facing challenges in operational clarity and regulatory hurdles, the company's scientific strengths and financial stability position it well to capitalize on opportunities for expanding collaborations and advancing novel therapeutic approaches.
With a focus on CNS delivery, tissue targeting, and surrogate markers, Voyager is poised to make significant strides in addressing neurological disorders and enhancing treatment efficacy, offering potential value for investors and patients alike.

Voyager Therapeutics reports strong Q1 earnings and strategic advancements

Voyager Therapeutics showcased robust financial performance and strategic advancements in neurotherapeutics and gene therapy, positioning the company for future growth.
While facing challenges related to animal model predictability and reimbursement considerations, Voyager is actively leveraging strengths in diversified therapeutic approaches and strategic partnerships.
Opportunities lie in exploring synergistic treatments, proactive risk mitigation, and innovative therapeutic strategies to address complex neurological disorders effectively.
Overall, Voyager's focus on innovation, strategic partnerships, and comprehensive drug development approaches underscores its commitment to advancing treatments for neurological diseases.

Voyager Therapeutics excels in Q2, poised for neurogenetic medicine expansion

Voyager Therapeutics demonstrated strong financial health, innovative advancements in CNS programs, and strategic partnerships driving revenue growth. While facing challenges in R&D management and program milestones, the company's opportunities lie in upcoming milestones and expansion in neurogenetic medicine.

Voyager Therapeutics advances CNS gene therapy with strong partnerships and cash balance

Voyager Therapeutics is making strides in CNS gene therapy delivery with strong financial backing
Facing challenges in toxicology studies and patient recruitment while eyeing collaboration opportunities
Opportunities lie in biomarker utilization, partnership models, and advancing key programs towards clinical milestones

Voyager Therapeutics reports robust earnings and advances in neurogenetic therapies

Voyager Therapeutics showcased a strong financial performance, progress in their pipeline programs, and a focus on innovation and differentiation in the gene therapy space.
While facing competition and regulatory challenges, the company's strategic strengths, collaborations, and positive data present opportunities for future growth and impact.
Analysts' inquiries into program progress and regulatory timelines underscore investor interest in Voyager's development trajectory and the potential of their neurogenetic therapies.
With a robust financial position, promising pipeline advancements, and a commitment to unique approaches, Voyager is poised to make significant strides in the treatment of neurological disorders.

Voyager Therapeutics excels in Q1, eyes Alzheimer's breakthroughs

Voyager Therapeutics demonstrated strong financial performance and pipeline advancements in Q1 2024.
The company's focus on neurogenetic medicine and innovative gene therapy programs is a key strength.
Challenges include demonstrating efficacy in ALS therapy and optimizing brain delivery methods.
Opportunities lie in exploring novel treatment approaches and anticipating key data releases.

Voyager Therapeutics excels in Q2 with innovative pipeline advancements

Voyager Therapeutics demonstrated strong performance in Q2 2024, focusing on key milestones, tau-directed programs, and derisking strategies.
While facing challenges in program optimization and competitive positioning, the company's strengths lie in innovative pipeline advancements and financial stability.
Opportunities for multi-organ specificity, disease-specific programs, and treatment refinement position Voyager for continued growth and therapeutic innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A. Kay, Krystof Bankiewicz, and Phillip Zamore in June 2013 and is headquartered in Lexington, MA.

Voyager (VYGR) signs agreement with Pfizer granting the latter with rights to develop novel capsids using Voyager's proprietary technology for Pfizer's gene therapies and options for exclusive license to the capsids.

Voyager (VYGR) Surges on Gene Therapy Deal With Pfizer

The stock price of Voyager Therapeutics Inc (NASDAQ: VYGR) increased by over 4% pre-market today. This is why it happened.

VYGR Stock: Why It Increased Today

Here's the big licensing news that's sending shares of VYGR stock higher today as investors reassess this company's value moving forward. The post VYGR Stock: The Huge Licensing Deal Sending Voyager Therapeutics Rocketing Higher appeared first on InvestorPlace.

VYGR Stock: The Huge Licensing Deal Sending Voyager Therapeutics Rocketing Higher

Voyager Therapeutics Inc (NASDAQ: VYGR) announced that the group had inked a license option agreement that allows Pfizer Inc. (NYSE: PFE). As news of the deal became official and was doing the rounds, the share value of Voyager spiked 55% on Wednesday morning.

Here's why Voyager Therapeutics is up 55%

The stock price of Voyager Therapeutics Inc (NASDAQ: VYGR) increased by over 50% pre-market today. This is why it happened.

VYGR Stock: Why It Drastically Increased Today

Shares of a small biotech called Voyager Therapeutics surged after the company said Pfizer had licensed access to its gene therapy technology in a deal worth up to $630 million.

Voyager Therapeutics Stock, a Beaten-Down Biotech, Soars on Pfizer License Deal

Voyager Therapeutics Inc (NASDAQ: VYGR) has announced licensing option agreement with Pfizer Inc (NYSE: PFE) for capsids generated from Voyager's RNA-driven TRACER screening technology. Related:   Voyager CEO Resigns After Company Turns Back To Discovery-Stage

Voyager Therapeutics Stock Soars On License Option Pact With Pfizer

Shares of Voyager Therapeutics Inc. VYGR, -3.52% rocketed 38.9% in premarket trading Wednesday, after closing at a record low in the previous session, after the gene therapy company announced a license option agreement with Pfizer Inc. PFE, -0.24% that could valued at more than $600 million. Trading volume spiked up to 3.9 million shares ahead of the open, which compares with the full-day average of about 173,000 shares.

Voyager Therapeutics stock rockets after license option deal with Pfizer that could be valued at $630 million

Voyager receives $30 million up front with potential option exercise fees and milestone payments of up to $600 million plus product sales-based royalties

Voyager Therapeutics Announces License Option Agreement with Pfizer for Next-Generation TRACERᵀᴹ AAV Capsids to Enable Neurologic and Cardiovascular Gene Therapy Programs

MeiraGTx Holdings plc

uniQure

Solid Biosciences

Sarepta Therapeutics

The promising gene therapy approach is being evaluated for varied diseases, such as hemophilia, Duchenne muscular dystrophy (DMD), Parkinson's disease, eye disease, and cancer among others

5 Gene Therapy Stocks Back in Focus on AbbVie/Regenxbio Deal

Proprietary AAV capsids to power second-generation efforts in Huntington's disease and ALS, pre-clinical programs in spinal muscular atrophy and diseases linked to GBA1 mutations

Voyager Therapeutics Transforms Pipeline and Increases Investment in Next-Generation TRACER™ AAV Capsid and Vectorized Antibody Platform Technologies

Voyager Therapeutics (VYGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Voyager Therapeutics (VYGR) to Report a Decline in Earnings: What to Look Out for

Voyager Therapeutics, Inc (NASDAQ: VYGR) CEO and President Andre Turenne will step down as the beleaguered company announced it would move focus to early, discovery-stage efforts. The company's CMO and R&D chief, Omar Khwaja, also stepped down after two years at the biotech.

Voyager CEO Resigns After Company Turns Back To Discovery-Stage

Company focusing on rapidly moving VY-HTT01 into clinical development for Huntington's disease and maximizing opportunities created by TRACER TM gene therapy technology platform and next-generation targeted AAV capsids

Voyager Therapeutics Announces Strategic Shift and Leadership Transitions

Voyager Therapeutics Inc (NASDAQ: VYGR) has announced new preclinical data characterizing the durable expression and activity of a vectorized anti-tau antibody. The results will be presented at the American Society of Gene and Cell Therapy.

Voyager Therapeutics' Vectorized Anti-Tau Antibody Shows Encouraging Preclinical Data In CNS Disorders

Findings to be presented at the 24 th Annual Meeting of the American Society of Gene and Cell Therapy

Voyager Therapeutics Presents New Preclinical Data Showing Reduction of Pathological Tau with Vectorized Anti-Tau Antibody

CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for serious neurological diseases, today will present new preclinical data demonstrating high transduction efficiency of the company's novel adeno-associated virus (AAV) capsids in the central nervous system (CNS) after intravenous dosing in non-human primates. Data will be presented at the 24th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) taking place virtually May 11-14, 2021.

Voyager Therapeutics' Novel Capsids Demonstrate Robust Delivery Across the Blood Brain Barrier, Widespread CNS Transduction in Non-Human Primates

- On track to initiate Phase 1/2 trial of VY-HTT01 for Huntington's disease in the fourth quarter of 2021

Voyager Therapeutics Announces First Quarter 2021 Financial Results and Corporate Updates

Earnings Preview: Voyager Therapeutics (VYGR) Q1 Earnings Expected to Decline

Voyager Therapeutics (VYGR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Strength Seen in Voyager Therapeutics (VYGR): Can Its 16.5% Jump Turn into More Strength?

Axsome Therapeutics

CRISPR Therapeutics

Reviva Pharmaceuticals

Voyager Therapeutics, Inc. (NASDAQ: VYGR), uniQure N.V. (NASDAQ: QURE), Axsome Therapeutics, Inc. (NASDAQ: AXSM), Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and CRISPR Therapeutics AG (NASDAQCRSP) are among the biggest biotech movers in Monday's session.

Why Voyager Therapeutics, uniQure, Axsome, Reviva Pharma and Crispr Are Moving Today

The stock price of Voyager Therapeutics Inc (NASDAQ: VYGR) has increased by over 13% during intraday trading this morning. This is why it happened.

VYGR Stock: Over 13% Increase Intraday Explanation

Today FDA has removed the clinical hold on one more gene therapy study, this time for Voyager Therapeutics Inc's (NASDAQ: VYGR) investigational new drug application for VY-HTT01, a gene therapy candidate for Huntington's disease (HD). The agency has confirmed that the company may proceed with its planned Phase 1/2 clinical trial.

Voyager Therapeutics' Stock Jumps As FDA Lifts Clinical Hold For Huntington's Disease Gene Therapy

Los Angeles, California--(Newsfile Corp. - March 24, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Voyager Therapeutics, Inc. ("Voyager" or "the Company") (NASDAQ: VYGR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between June 1, 2017 and November 9, 2020,...

DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Voyager Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

NEW YORK, March 24, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Voyager Therapeutics, Inc. ("Voyager" or the "Company") (NASDAQ: VYGR) and certain of its officers. The class action, filed in United States District Court for the Eastern District of New York, and docketed under 21-cv-00381, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Voyager securities between June 1, 2017 and November 9, 2020, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Voyager Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - VYGR

News for Voyager Therapeutics Stock (VYGR)